The present invention is directed to imidazo [1, 2-b] [1, 2, 4] triazines and imidazo [1, 2-a] pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.本發明係關於咪唑并[1,2-b][1,2,4]三化物及咪唑并[1,2-a]嘧啶化物,及其醫藥組合物,其為激酶諸如c-Met之抑制劑,適用於治療與激酶路徑失調相關之癌症及其他疾病。